[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100280520":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PBC patients",null,"Patients with primary biliary cholangitis",[13,14,15,16],"Other: Blood samples","Device: Fibroscan","Other: Questionnaires","Biological: Liver biopsy",[18,21,25,28],{"type":6,"name":19,"description":10,"armGroupLabels":20,"otherNames":10},"Blood samples",[9],{"type":22,"name":23,"description":10,"armGroupLabels":24,"otherNames":10},"DEVICE","Fibroscan",[9],{"type":6,"name":26,"description":10,"armGroupLabels":27,"otherNames":10},"Questionnaires",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"BIOLOGICAL","Liver biopsy","Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)",[9],[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Lars Bossen, PhD-student","CONTACT","+4522800676","larsbossen@clin.au.dk",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark","RECRUITING","Aarhus C","Central Jutland","8000","Denmark","DK",{"type":49,"coordinates":50},"Point",[51,52],10.21231,56.16558,{"lat":52,"lon":51},[55],{"name":35,"role":36,"phone":56,"phoneExt":10,"email":38},"+45 2280 0676",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100280520","scd163-in-pbc-patients---assessment-of-treatment-response-100280520",false,"NCT02931513","sCD163 in PBC Patients - Assessment of Treatment Response","Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA","Inclusion Criteria:\n\n* Newly diagnosed with Primary biliary cholangitis\n* No treatment with UDCA\n\nExclusion Criteria:\n\n* Patient under 18 years\n* Expected lifetime under 6 months\n* Expected liver transplantation within 6 months\n* Liver cancer\n* Cirrhosis from other causes","ALL","18 Years",{"count":69,"type":70},40,"ESTIMATED","OBSERVATIONAL","Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment.\n\nsCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.",[74,75,76],"Primary Biliary Cirrhosis","Liver Inflammation","Ursodeoxycholic Acid","2022-08-11",{"date":79,"type":80},"2022-08-12","ACTUAL",{"date":82,"type":10},"2016-09",{"date":84,"type":70},"2031-09",{"name":5,"class":6},1]